Feb 12, 2019 8:00am EST Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium
Feb 06, 2019 8:30am EST Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th
Jan 22, 2019 8:30am EST Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer
Jan 15, 2019 8:00am EST Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019
Jan 14, 2019 8:00am EST Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia
Dec 13, 2018 6:30am EST Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter
Dec 06, 2018 8:30am EST Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th
Dec 03, 2018 8:30am EST Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia
Nov 13, 2018 8:30am EST Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer
Oct 01, 2018 7:30am EDT First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy
